|
Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma
|
29 May 2019 |
|
Bayer reaches settlement to resolve Xarelto™ litigation
|
25 March 2019 |
|
Bayer is taking collaboration with health care start-ups to the next level
|
21 March 2019 |
|
Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
|
07 March 2019 |
|
Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
|
28 February 2019 |
|
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)
|
15 February 2019 |
|
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
|
03 December 2018 |
|
U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
|
28 November 2018 |
|
Bayer accelerates six new startups
|
30 August 2018 |
|
Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
|
06 August 2018 |
|
XANTUS programme confirms low bleeding and low stroke rate with Xarelto® in 11,121 prospectively investigated patients with atrial fibrillation
|
10 July 2018 |
|
Bayer expands strategic alliance with Broad Institute of MIT and Harvard
|
04 July 2018 |
|
Combining tradition with modernity: Bayer hones its brand profile
|
04 April 2018 |
|
Bayer announces publication of larotrectinib data in The New England Journal of Medicine
|
26 February 2018 |
|
FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice
|
16 January 2018 |
|
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
|
17 November 2017 |
|
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
|
21 September 2017 |
|
Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
|
23 March 2017 |
|
Another record year for Bayer - good progress with the acquisition of Monsanto
|
22 February 2017 |
|
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early
|
14 February 2017 |